Kineta, Inc.
http://www.kinetabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kineta, Inc.
Finance Watch: Kronos Reveals Second Round Of Job Cuts In Five Months
Restructuring Edition: Kronos restructured and cut 19% of its workforce in November and now will cut 21% of its remaining jobs. Also, Gritstone cut 40% of its workforce after missing out on an expected external funding payment and Kineta implemented a 64% workforce reduction.
Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut
After its August 2020 reverse merger, neuroscience-focused Yumanity is calling it quits with two transactions: an asset sale to Janssen and a merger with private cancer immunotherapy firm Kineta.
Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- ADMET
-
Molecular Diversity
- Natural Products
-
Large Molecule
- Other Names / Subsidiaries
-
- Kineta Immuno-oncology, LLC
- Kineta RLB
- KPI Therapeutics, Inc.
- Kineta Chronic Pain, LLC
- Yumanity Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice